FIGURE 5.

Wogonin ameliorates septic liver injury in a Nrf2‐dependent manner. A and B, MDA and SOD activity in AML12 cells with indicated treatments. C, Intracellular ROS analysed by flow cytometry and represented as MFI of CM‐H₂DCFDA in AML12 cells. D, Immunoblotting analysis of Nrf2, NQO‐1, GST‐M1, HO‐1, SOD1 and SOD2 in AML12 cells with indicated treatments. E and F, qRT‐PCR analysis of TNF‐α, IL‐1β and IL‐6 mRNA levels and immunoblotting analysis of p65 and p‐p65 (Ser536) in AML12 cells with indicated treatments. G, Representative flow cytometry images and analysis of cell apoptosis in AML12 cells with indicated treatments. H, Immunoblotting analysis of Nrf2, pro‐apoptotic Bax, Cleaved‐Caspase3 and Cleaved‐PARP together with anti‐apoptotic Bcl2 expression and densitometry analysis of Cleaved‐caspase3 and Cleaved‐PARP. The concentration of wogonin is 10 μmol/L. The results are presented as mean ± SD through at least 3 independent experiments and were analysed by two‐tailed Student's t test or one‐way analysis of variance (ANOVA). ns, no statistical significance, *P < .05, **P < .01, ***P < .001